Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 9Lymphoma, Non-Hodgkin 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Follicular 5Lymphoma 5Lymphoma, B-Cell 3Leukemia 3Recurrence 2Lymphoma, Mantle-Cell 2Solid Tumors 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myeloid, Acute 1Indolent Non-Hodgkin's Lymphoma 1Hodgkin Disease 1Hereditary Sensory and Autonomic Neuropathies 1Disease 1Colorectal Neoplasms 1Bronchiolitis Obliterans Syndrome 1Breast Neoplasms 1B-cell Malignancies 1

Interventions

tirabrutinib 1obinutuzumab 1idelalisib 1Influenza Vaccines 16-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × B-cell Malignancies × obinutuzumab × Clear all
NCT02457598 2025-06-17

Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies

Gilead Sciences

Phase 1 Terminated
203 enrolled 43 charts
Lymphoid

B-cell Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡